Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul;74(7):743-54.
doi: 10.1097/NEN.0000000000000213.

KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas

Aline Paixão Becker  1 , Cristovam Scapulatempo-Neto, Adriana C Carloni, Alessandra Paulino, Jamie Sheren, Dara L Aisner, Evelyn Musselwhite, Carlos Clara, Hélio R Machado, Ricardo S Oliveira, Luciano Neder, Marileila Varella-Garcia, Rui M Reis
Affiliations

KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas

Aline Paixão Becker et al. J Neuropathol Exp Neurol. 2015 Jul.

Abstract

Up to 20% of patients with pilocytic astrocytoma (PA) experience a poor outcome. BRAF alterations and Fibroblast growth factor receptor 1 (FGFR1) point mutations are key molecular alterations in Pas, but their clinical implications are not established. We aimed to determine the frequency and prognostic role of these alterations in a cohort of 69 patients with PAs. We assessed KIAA1549:BRAF fusion by fluorescence in situ hybridization and BRAF (exon 15) mutations by capillary sequencing. In addition, FGFR1 expression was analyzed using immunohistochemistry, and this was compared with gene amplification and hotspot mutations (exons 12 and 14) assessed by fluorescence in situ hybridization and capillary sequencing. KIAA1549:BRAF fusion was identified in almost 60% of cases. Two tumors harbored mutated BRAF. Despite high FGFR1 expression overall, no cases had FGFR1 amplifications. Three cases harbored a FGFR1 p.K656E point mutation. No correlation was observed between BRAF and FGFR1 alterations. The cases were predominantly pediatric (87%), and no statistical differences were observed in molecular alterations-related patient ages. In summary, we confirmed the high frequency of KIAA1549:BRAF fusion in PAs and its association with a better outcome. Oncogenic mutations of FGFR1, although rare, occurred in a subset of patients with worse outcome. These molecular alterations may constitute alternative targets for novel clinical approaches, when radical surgical resection is unachievable.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Molecular alterations in BRAF. (A, B) FISH assay for detection of KIAA1549:BRAF fusion showing a positive (A) and a negative (B) case (white arrows). (C, D) Point mutations detected by Sanger sequencing for V600E (C) and V600K (D).
FIGURE 2
FIGURE 2
Immunohistochemical expression of FGFR1. (A) In normal cerebellum, expression is limited to Purkinje cells. (B) Neoplastic cells show overexpression when compared with nonneoplastic astrocytes (bottom). (C) Oligodendroglial pattern of PA, showing moderate FGFR1 expression. (D) Piloid pattern of PA with similar FGFR1 expression.
FIGURE 3
FIGURE 3
Molecular alterations of FGFR1. (A) Electropherogram showing the point mutation K656E. (B, C) FISH assay displaying a normal pattern (B), and a case with low-copy number gain of the FGFR1 signal (C). The amount of FGFR1 signals (green) did not reach the cutoff value needed for the diagnosis of gene amplification.
FIGURE 4
FIGURE 4
(A–D) Kaplan-Meier curves showing the impact of KIAA1549:BRAF (K:B) fusion (A, B) and FGFR1 p.K656E point mutation (C, D) in the overall survival and event-free survival of the patients.
FIGURE 5
FIGURE 5
Kaplan-Meier curves comparing the simultaneous impact of KIAA1549:BRAF (K:B) fusion and FGFR1 alterations on the overall survival of patients. (A) Impact of FGFR1 p.K656E point mutation. (B) Impact of FGFR1 expression assessed by immunohistochemistry (positive score ≥3; negative score ≤2).
See this image and copyright information in PMC

References

    1. Scheithauer BW, Hawkins C, Tihan T, et al. Pilocytic astrocytoma. In: David N, Louis MD, Hiroko Ohgaki PD, Otmar D, Wiestler MD, Webster K, Cavenee PD, editors. WHO Classification of Tumours of the Central Nervous System. World Health Organization Classification of Tumours. Lyon, France: IARC Press, 2007: 13– 21
    1. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64: 83– 103 - PubMed
    1. Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 2012; 14 (Suppl 5): v1– 49 - PMC - PubMed
    1. Camargo Bd, Felipe CFP, Noronha CP, et al. Câncer na criança e no adolescente no Brasil dados dos registros de base populacional e de mortalidade. Rio de Janeiro: Instituto Nacional do Câncer, 2008
    1. Rosemberg S, Fujiwara D. Epidemiology of pediatric tumors of the nervous system according to the WHO 2000 classification: a report of 1,195 cases from a single institution. Child Nerv Sys 2005; 21: 940– 4 - PubMed

Publication types

MeSH terms

Substances